ESR1 and breast cancer: Preclinical data indicate that mutations in GATA3 also affect ER binding to DNA [22, 24], modulate response of breast cancer cells to estrogen signaling [25], could promote tumor growth [21, 26] and could be associated with endocrine resistance [25].